Eptinezumab plus education reduces monthly migraine days in adults with chronic migraine and medication-overuse headache.

FDA issues a Complete Response Letter to Grace Therapeutics for GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage.

Optimal sleep appears to offer some protection against risk for dementia, with improved effects among people with focal epilepsy.

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

Proximal hypoglossal nerve stimulation offers a clinically significant response for adults with obstructive sleep apnea.

Type 1 diabetes mellitus is associated with a significantly increased risk for incident dementia compared with type 2 diabetes mellitus among older adults.

What was the primary hypothesis of the OCEANIC-STROKE trial, and did the final data meet your expectations?” Dr Sharma: ...

Could you provide an overview of the Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment (DUET) ...

Test your knowledge on neurology research presented at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Adolescent food insecurity is significantly linked to increased risks for depression, concussion, and inadequate sleep, ...

Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.

Ocrelizumab shows the highest association with urinary tract infections in patients with MS according to an FDA Adverse Event ...